Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
- Mechanism
- Curator reviewed · 3 references
Depatuxizumab is a chimeric monoclonal antibody for EGFR which is linked to monomethyl aurastatin F via a maleimidocaproyl linker (mafodotin). Once delivered to the cancer cell, the mafodotin component is able to bind to tubulin and inhibit the exchange of GDP for GTP necessary for the polymerization of tubulin subunits to form microtubules. The inhibition of microtubule polymerization disrupts mitosis and interferes with vesicle trafficking in the cancer cell.
- Primary indication
- No approved indication.Curator reviewed
- Also known as
- Denintuzumab mafodotin
- Code names
- 1399672-02-6 · ABT-414 · SGN-19A · SGN-CD 19A
Resolves to
What you can answer from here — as of August 31, 2026
Which drugs share a target with Depatuxizumab mafodotin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account